COX-II inhibitors - A new generation of safer NSAIDs?

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 2, 1997, Pages 227-235

  Donnelly, M T ^a   Hawkey, C J ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 FLUOROPHENYL) 2 [(4 METHYLSULFONYL)PHENYL]CYCLOPENTENE; 4 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 2 METHYL 1,2 OXAZIN 3 ONE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; CELECOXIB; D 1367; DICLOFENAC; FLOSULIDE; IBUPROFEN; IGURATIMOD; INDOMETACIN; L 748731; L 761066; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ICOSANOID; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; COLORECTAL TUMOR; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; EICOSANOIDS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; THIAZINES; THIAZOLES;

EID: 0031113915     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.154330000.x     Document Type: Review

References (92)

1. Gross M, Greenberg LA. The Salicylates. A Critical Bibliographic Review. New Haven, CT: Hillhouse Press, 1948: 95.
2. Douthwaite A, Lintot CA. Gastroscopic observations of the effect of aspirin and certain other substances on the stomach. Lancet 1938; ii: 1222.
3. Coggon D, Langman MJS, Spiegelhalter D. Aspirin, paracetamol, haematemesis and melaena. Gut 1982; 23: 340-4.
4. Coggon D, Lambert P, Langman M. 20 years of hospital admissions with peptic ulcer in the United Kingdom. Lancet 1981; i: 1302-4.
5. Somerville K, Faulkner G, Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet 1986; i: 462-6.
6. Walt R, Katschinski B, Logan R, Ashley J, Langman M. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet 1986; i: 489-92.
7. Hawkey CJ. Non-steroidal anti-inflammatory drugs and ulcers: facts and figures multiply but do they add up? Br Med J 1990; 300: 278-84.
8. Henry D, Robertson J. Nonsteroidal anti-inflammatory drugs and peptic ulcer hospitalization rates in New South Wales. Gastroenterology 1993; 104: 1083-91.
9. Carty TJ, Marfat A. COX-2 inhibitors. Potential for reducing NSAID side-effects in treating inflammatory diseases. Emerging Drugs 1996; 391-413.
10. Caldwell JR. Sucralfate in the relief of gastrointestinal symptoms associated with nonsteroidal anti-inflammatory drugs. Southern Med J 1985; 78: 938-40.
11. Caldwell JR, Roth SH, Wu WC, et al. Sucralfate treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal symptoms and damage. Am J Med 1987; 83: 74-82.
12. Stiel D, Ellard KT, Hills LJ, Brooks PM. Protective effect of enprostil against aspirin induced gastroduodenal mucosal injury in man. Comparison with cimetidine and sucralfate.Am J Med 1986; 81: 54-8.
13. 2-receptor antagonists in peptic ulcer disease: evidence for a prophylactic use. Drugs 1994; 47: 862-71.
14. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-9.
15. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal antiinflammatory drugs. New Engl J Med 1996; 334: 1435-9.
16. Hawkey CJ, Swannell AJ, Eriksson S, et al. Benefits of omeprazole over misoprostol in healing NSAID associated ulcers. Gastroenterology 1996; 110: A131 (Abstract).
17. Hawkey CJ, Swannell AJ, Eriksson S, et al. Lower frequency of gastroduodenal ulcers and erosions and dyspeptic symptoms in NSAID users during maintenance with omeprazole compared to ranitidine. Gastroenterology 1996; 110: A131 (Abstract).
18. Florence AT, Jani PU. Novel oral drug formulations: Their potential in modulating adverse events. Drug Safety 1994; 10: 233-66.
19. Lipscomb GR, Rees WDW. Gastric mucosal injury and adaptation to oral and rectal administration of naproxen. Aliment Pharmacol Ther 1996; 10: 298-303.
20. Grahame R. Transdermal non-steroidal anti-inflammatory agents. Br J Clin Prac 1995; 49: 33-5.
21. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971; 231: 232-5.
22. Marnett L. Aspirin and the potential role for prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-89.
23. Smith WL, Marnett LJ. Prostaglandin endoperoxide synthase: Structure and catalysis. Biochem Biophys Acta 1991; 1083: 1-17.
24. 2 synthase-1. Nature 1994; 367: 243-9.
25. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073-6.
26. Eberhart CE, Du Bois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology 1995; 109: 285-301.
27. Robert A. Cytoprotection by prostaglandins. Gastroenterology 1969; 77: 761.
28. Feldman M, Colturi TJ. Effect of indomethacin on basal histamine stimulated gastric acid secretion. Gastroenterology 1984; 87: 1339-43.
29. Winship DH, Barnhard GC. Basal and histamine-stimulated human gastric acid secretion : lack of effect of indomethacin in therapeutic doses. Gastroenterology 1970; 58: 762-6.
30. Lawson LD, Powell DW. Bradykinin-stimulated eicosanoid synthesis and secretion by rabbit ileal components. Am J Physiol 1987; 25: G783-90.
31. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cycloxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-8.
32. Main IHM, Whitle BJR. The effects of E and A prostaglandin on gastric mucosal blood flow and acid secretion in the rat. Br J Pharmacol 1973; 49: 428.
33. Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by non-steroidal anti-inflammatory drugs is a neutrophil dependent process. Am J Physiol 1990; 259: G462.
34. 2 metabolism. Gut 1992; 33: 164-9.
35. Hull MA, Cullen DJE, Atherton JC, Hawkey CJ. Basic fibroblast growth factor and transforming growth factor alpha and gastric ulceration. Gut 1993; 34: S51 (Abstract).
36. Levi S, Goodlad RA, Lee CY, et al. Inhibitory effect of non-steroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing. Lancet 1990; 336: 840-3.
37. Moncada, S, Grygewlski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-5.
38. Salvemini D, Misko TP, Masferre JL, et al. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993; 90: 7240-4.
39. Allison MC, Howat AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. New Engl J Med 1992; 327: 749-54.
40. 2 synthase (cydooxygenase) in human monocytes. J Biol Chem 1990; 265: 16737-40.
41. Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990; 86: 1375-9.
42. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal anti-inflammatory drugs. Drug Dev Res 1992; 25: 249-65.
43. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-5.
44. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/ cyclooxygenase homologue. J Biol Chem 1991; 266: 12866-72.
45. Lee SH, Soyoola E, Chanmugam P, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992; 267(36): 25934-8.
46. Du Bois RN, Awad J, Morrow J, et al. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-α and phorbol ester. J Clin Invest 1994; 93: 493-8.
47. Coyne DW, Nickols M, Bertrand W, et al. Regulation of mesangial cell cyclooxygenase synthesis by cytokines and glucocorticoids. Am J Physiol 1992; 263: F97-102.
48. Simmons DL, Levy DB, Yannoni Y, et al. Identification of a phorbol ester-repressible v-src-inducible gene. Proc Natl Acad Sci USA 1989; 86: 1178-82.
49. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44: 1-10.
50. Ren Y, Loose Mitchell DS, Kulmacz RJ, Prostaglandin H synthase-1 : Evaluation of C-terminus function. Arch Biochem Biophys 1995; 316: 751-7.
51. Distel M, Mueller C, Blumkhi E, Fries J. Safety of meloxicam: A global analysis of clinical trials. Br J Rheum 1996; 35: S168-77.
52. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8.
53. Garcia-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72.
54. Lipani JA, Poland M. Clinical update of the relative safety of nabumetone in long-term clinical trials. Inflammopharmacology 1995; 3: 351-61.
55. Trummlitz G, Engelhardt G, Busch U. Meloxicam. Drugs of Future. 1989; 14: 1047-8.
56. Pairet M, Engelhardt G. The preferential inhibition of COX-2 by meloxicam is highly dependent on the structure of the drug. Rheumatol Eur 1995; 24(Suppl. 3): 272.
57. Engelhardt G, Homma D, Schnitzler C. Meloxicam: A potent inhibitor of adjuvant arthritis in the Lewis rat. Inflamm Res 1995; 44: 548-55.
58. Patoia L, Santucci L, Furno P, et al. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheum 1996; 35: S161-7.
59. Wotjulewski JA, Schattenkirchner M, Barcelo P, et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5mg daily and naproxen 750mg daily in patients with rheumatoid arthritis. Br J Rheum 1996; 35: S122-8.
60. Vane JR, Bjarnason I, Fenner H. Meloxicam. Drugs 1996; 51: 431-2.
61. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits COX-2 activity in vitro. Prostaglandins 1994; 47: 55-9.
62. Gans KR, Galbraith W, Roman RJ, et al. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 1990; 254: 180-7.
63. Bendele AM, Benslay DN, Hom JT, et al. Anti-inflammatory activity of BF389, a di-T-butylphenol, in animal models of arthritis. J Pharm Exp Ther 1992; 260: 300-5.
64. Wiesenberg-Boettcher I, Schweizer A, Green JR, Mueller K, Maerki F, Pfeilschifter J. The pharmacological profile of CGP 28238, a novel highly potent anti-inflammatory compound. Drugs Exp Clin Res 1989; 15: 501-9.
65. Davis R, Brogden RN. Nimesulide: an update on its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs, 1994; 48: 431-54.
66. Black WC, Belley M, Chan C, et al. From indomethacin to a selective COX-2 inhibitor: development of indolalkalonic acids as potent and selective cyclooxygenase-2 inhibitors. Inflamm Res 1995; 44(Suppl. 3): S270.
67. Chan CC, Boyce S, Brideau C, et al. Pharmacology of a selective cyclooxygenase inhibitor, L-745.337: A novel non-steroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharm Exp Ther 1995; 274: 1531-7.
68. Leblanc Y, Black WC, Chan CC, et al. Synthesis and biological evaluation of both enantiomers of L-761,000 as inhibitors of cyclooxygenase 1 and 2. Bioorg Med Chem Lett 1996; 6: 731-6.
69. Tanaka K, Kawasaki H, Kurata K, Aikawa Y, Tsukamoto Y, Inaba T. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase 2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol 1995; 67: 305-14.
70. Tofanetti O, Casciarri I, Cipolla PV, Cazzulani P, Omini C. Effect of nimesulide on cyclooxygenase activity in rat gastric mucosa and inflammatory exudate. Med Sci Res 1989; 17: 745-6.
71. Davis R, Brogden RN. Nimesulide. An update on its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431-54.
72. Fusetti G, Magni E, Armadola MC. Tolerability of nimesulide: Epidemiological data. 1993; 46: S1277-80.
73. Crankshaw DJ, Dyal R. Effects of some naturally occurring prostanoids and some cyclooxygenase inhibitors on the contraction of the human uterine segment in vivo. Can J Phys Pharm 1994; 870-4.
74. Harris RC, McKanna JA, Akai Y, Jacobson HR, Du Bois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of the kidney and increases with salt restriction. J Clin Inv 1994; 94: 2504-10.
75. Donnelly MT, Bishop AE, Polak J, Hawkey CJ. Elevated inducible cyclooxygenase in H. pylori infected gastric mucosa and gastric cancer. Gastroenterology 1996; 110: A897 (Abstract).
76. Schmassmann A, Settler C, Netzer P, Flogerzi B, Peskar B, Halter F. L-745, 337, a selective inhibitor of COX-2, delays healing of experimental gastric ulcers comparable to traditional NSAIDs. Gastroenterology 1996; 110: A252 (Abstract).
77. Bjarnason I, Hayllar J, MacPherson, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832-47.
78. Lanchbury JS, Pitzalis C. Cellular immune mechanisms in rheumatoid arthritis and other inflammatory arthritides. Curr Op Immun 1993; 5: 918-24.
79. Morham SG, Langerbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83: 473-82.
80. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Onc 1983; 24: 83-7.
81. Peleg I, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Int Med 1994; 154: 394-9.
82. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1995; 109: 285-301.
83. Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Inv 1995; 96: 491-503.
84. Tsujii M, Du Bois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
85. Elliott SN, McKnight W, Cirino G, Wallace JL. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995; 109: 524-30.
86. Lichtenberger LM, Wang ZM, Romero JJ, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids : Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1995; 1: 154-8.
87. Pairet M, Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. In: Vane J, Botting J, Botting R, eds. Improved Non-steroidal Anti-inflammatory Drugs. Dordrecht/Boston/London: Kluwer Academic, 1996: 103-19.
88. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of non-steroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci 1994; 90: 11693-7.
89. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156-60.
90. Klein T, Nusing RM, Pfeilschifter J, Ullrich V. Selective inhibition of cyclooxygenase 2. Biochem Pharm 1994; 48: 1605-10.
91. Tavares IA, Bennett A. Acemetacin and indomethacin: Differential inhibition of constitutive and inducible cyclooxygenases in human gastric mucosa and leucocytes. Int J Tissue React 1993; 15: 49-53
92. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterisation of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharm Exp Ther 1994; 271: 1705-12.